ADMA BIOLOGICS, INC.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
Repurchases of Equity Securities
In May 2025, the Board authorized a share repurchase program of up to $500.0 million of our outstanding shares of common stock (the “Repurchase Program”). The Repurchase Program does not obligate us to acquire any particular amount of our common stock, and may be modified, suspended, or terminated at any time. The Repurchase Program has no expiration date.
During the three and nine months ended September 30, 2026, in addition to the shares repurchased under the ASR Agreement, we repurchased 2,722,563 and 5,777,770 shares of common stock under the Repurchase Program at a total cost of $25.1 million and $55.3 million, respectively.
Index
Accelerated Share Repurchase Program
On March 2, 2026, we entered into the ASR Agreement with JPMorgan to repurchase $125.0 million of shares of our common stock under the Repurchase Program. During the three and nine months ended September 30, 2026, we received 0 and 10,760,487 shares of common stock, respectively, pursuant to the terms of the ASR Agreement.
The table below reflects shares of common stock we repurchased during the third quarter of 2026:
| For the Month Ended · Total Number of Shares Purchased · Average Price Paid per Share (1) · Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs · Approximate Dollar Value of shares that may yet be Purchased Under the Plans or Programs (2) | |||||
|---|---|---|---|---|---|
| July 31, 2026 | 1,418,913 | $8.83 | 1,418,913 | $300,286,118 | |
| August 31, 2026 | 1,303,650 | $9.61 | 1,303,650 | $287,760,037 | |
| September 30, 2026 | - | $ | - | - | $287,760,037 |
| Total | 2,722,563 | $9.22 | 2,722,563 | ||
(1) Includes broker commissions.
(2) Shares were repurchased pursuant to our share repurchase program publicly announced on May 5, 2025. There is no expiration date for this share repurchase program. The authorization to repurchase shares will end when we have repurchased the maximum number of shares authorized, or if we have determined to terminate such program.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.